Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec 27;14(1):547-62.
doi: 10.3390/ijms14010547.

Dendritic cells and multiple sclerosis: disease, tolerance and therapy

Affiliations
Review

Dendritic cells and multiple sclerosis: disease, tolerance and therapy

Mohammad G Mohammad et al. Int J Mol Sci. .

Abstract

Multiple sclerosis (MS) is a devastating neurological disease that predominantly affects young adults resulting in severe personal and economic impact. The majority of therapies for this disease were developed in, or are beneficial in experimental autoimmune encephalomyelitis (EAE), the animal model of MS. While known to target adaptive anti-CNS immune responses, they also target, the innate immune arm. This mini-review focuses on the role of dendritic cells (DCs), the professional antigen presenting cells of the innate immune system. The evidence for a role for DCs in the appropriate regulation of anti-CNS autoimmune responses and their role in MS disease susceptibility and possible therapeutic utility are discussed. Additionally, the current controversy regarding the evidence for the presence of functional DCs in the normal CNS is reviewed. Furthermore, the role of CNS DCs and potential routes of their intercourse between the CNS and cervical lymph nodes are considered. Finally, the future role that this nexus between the CNS and the cervical lymph nodes might play in site directed molecular and cellular therapy for MS is outlined.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lassmann H., van Horssen J., Mahad D. Progressive multiple sclerosis: Pathology and pathogenesis. Nat. Rev. Neurol. 2012;8:647–656. - PubMed
    1. Antel J., Antel S., Caramanos Z., Arnold D.L., Kuhlmann T. Primary progressive multiple sclerosis: Part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 2012;123:627–638. - PubMed
    1. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009;9:393–407. - PMC - PubMed
    1. Patsopoulos N.A., Esposito F., Reischl J., Lehr S., Bauer D., Heubach J., Sandbrink R., Pohl C., Edan G., Kappos L., et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol. 2011;70:897–912. - PMC - PubMed
    1. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., Dilthey A., Su Z., Freeman C., Hunt S.E., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214–219. - PMC - PubMed

MeSH terms